Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Cann Group Ltd. ( (AU:CAN) ).
Cann Group Limited announced that the National Australia Bank has agreed to extend the maturity dates of its construction loan and working capital facility from May to September 2025, alongside deferring the next two quarters of interest payments totaling about $1.8 million. This move is part of Cann Group’s ongoing financial management efforts, as they also engage with a private credit fund lender for similar assistance. Such financial adjustments are likely to aid Cann Group in maintaining its operational stability and support its strategic growth within the cannabis industry.
More about Cann Group Ltd.
Cann Group Limited is an Australian company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. The company operates research facilities and corporate headquarters in Melbourne and has a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group provides a variety of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers both domestically and internationally. Additionally, Cann Group owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: 190.91%
Average Trading Volume: 1,516
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.25M
Find detailed analytics on CAN stock on TipRanks’ Stock Analysis page.
